BI-2493 (90 mg/kg, p.o., twice daily for 21 days) exhibits tumor-suppressive activity in LS513/GP2d/HPAC/SW620/MIAPACA2-derived xenograft NMRI mice models[1].
| Animal Model: | LS513/GP2d/HPAC/SW620/MIAPACA2-derived xenograft NMRI mice models |
| Dosage: | 90 mg/kg |
| Administration: | Oral gavage (p.o.), twice daily for 21 days |
| Result: | Reduced tumor growth in mice carrying KRAS G12C, G12D, G12V, and A146V mutation models, without causing significant toxicity to the mice. |
